Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 11, 2024, covering events occurring on January 7, 2024. Precision BioSciences, Inc. (DTIL), a biotechnology company focused on gene editing, entered into a material definitive agreement to license its allogeneic CAR T therapy, azer-cel, for non-oncological applications.
Key Financial Metrics and Liquidity
- Liquidity: The Company estimates approximately $116 million in cash and cash equivalents as of December 31, 2023 (unaudited and preliminary).
- Upfront Consideration: The Company is entitled to an upfront payment of $10.0 million under the new agreement.
- Payment Structure: The upfront payment consists of $5.25 million in immediate cash, $2.25 million in cash exchanged for Company common stock, and a deferred $2.5 million cash payment also exchanged for stock.
- Runway: Management expects existing cash, operational receipts, and the new agreement consideration to fund operations into the first half of 2026.
Material Changes and Agreements
On January 7, 2024, the Company signed a License Agreement with TG Cell Therapy, Inc. (a subsidiary of TG Therapeutics, Inc.). Key terms include:
- Licensing Scope: Exclusive and non-exclusive rights for TG Therapeutics to develop, manufacture, and commercialize non-oncological applications of azer-cel.
- Milestone Payments: An initial milestone payment of $7.5 million is expected in the near-term upon achieving a specific clinical milestone. Additional milestone payments of up to $288.6 million are contingent on future achievements.
- Stock Issuance: Up to $10.0 million of the upfront and initial milestone payments will be settled via the issuance of Company common stock to TG Therapeutics. The share price is calculated at 200% of the 30-day VWAP, with a floor price of $0.3722 per share.
- Royalties: TG Therapeutics must pay tiered royalties ranging from mid-single digit to low-double digit percentages on net sales of the Licensed Product.
- Control Provisions: TG Therapeutics has agreed to vote the acquired shares as instructed by the Company for three years and is restricted from initiating change-of-control transactions for the same period.
Outlook, Risks, and Management Commentary
Management anticipates that the agreement will support the Company's cash runway to achieve first-in-human Phase 1 clinical data for its lead in vivo gene editing programs. The filing includes extensive forward-looking statements regarding clinical development, regulatory approval, and the ability to raise additional capital. Risks cited include the Company's limited operating history, dependence on ARCUS technology, potential manufacturing challenges, and the uncertainty of achieving clinical milestones.
Investor Verification Checklist
- Verify the final audited cash balance as of December 31, 2023, in the upcoming Form 10-K.
- Confirm the exact number of shares to be issued upon the $2.25 million and $2.5 million stock-settled payments based on the 30-day VWAP calculation.
- Monitor the achievement of the near-term clinical milestone required to trigger the $7.5 million initial milestone payment.
- Review the full text of the License Agreement (to be filed as an exhibit to the 2023 Form 10-K) for specific termination rights and royalty calculation details.
- Assess the impact of the stock issuance on existing shareholder dilution and the Company's capital structure.